3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

NCT00381550 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Accelerated Phase Chronic Myelogenous Leukemia
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blastic Phase Chronic Myelogenous Leukemia
Chronic Eosinophilic Leukemia
Chronic Myelomonocytic Leukemia
Essential Thrombocythemia
Philadelphia Chromosome Negative Chronic Myelogenous Leukemia
Polycythemia Vera
Primary Myelofibrosis
Relapsing Chronic Myelogenous Leukemia

Interventions

DRUG: fludarabine phosphate
DRUG: triapine
PROCEDURE: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)